|
1
|
Matz MH: Benign cystic teratomas of the
ovary: a review. Obstet Gynecol Surv. 16:591–594. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lakkis WG, Martin MC and Gelfand MM:
Benign cystic teratoma of the ovary: a 6-year review. Can J Surg.
28:444–446. 1985.PubMed/NCBI
|
|
3
|
Ayhan A, Bukulmez O, Genc C, Karamursel BS
and Ayhan A: Mature cystic teratomas of the ovary: case series from
one institution over 34 years. Eur J Obstet Gynecol Reprod Biol.
88:153–157. 2000.PubMed/NCBI
|
|
4
|
Emin U, Tayfun G, Cantekin I, Ozlem UB,
Umit B and Leyla M: Tumor markers in mature cystic teratomas of the
ovary. Arch Gynecol Obstet. 279:145–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park SB, Kim JK, Kim KR and Cho KS:
Imaging findings of complications and unusual manifestations of
ovarian teratomas. Radiographics. 28:969–983. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shah AA, Meese E and Blin N: Profiling of
regulatory microRNA transcriptomes in various biological processes:
a review. J Appl Genet. 51:501–507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Corney DC, Hwang CI, Matoso A, Vogt M,
Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH,
Hermeking H and Nikitin AY: Frequent downregulation of miR-34
family in human ovarian cancers. Clin Cancer Res. 16:1119–1128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhattacharya R, Nicoloso M, Arvizo R, Wang
E, Cortez A, Rossi S, Calin GA and Mukherjee P: MiR-15a and MiR-16
control Bmi-1 expression in ovarian cancer. Cancer Res.
69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miura K, Obama M, Yun K, Masuzaki H, Ikeda
Y, Yoshimura S, Akashi T, Niikawa N, Ishimaru T and Jinno Y:
Methylation imprinting of H19 and SNRPN genes in human benign
ovarian teratomas. Am J Hum Genet. 65:1359–1367. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lakshmipathy U, Love B, Goff LA, Jornsten
R, Graichen R, Hart RP and Chesnut JD: MicroRNA expression pattern
of undifferentiated and differentiated human embryonic stem cells.
Stem Cells. 16:1003–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
von Frowein J, Pagel P, Kappler R, von
Schweinitz D, Roscher A and Schmid I: MicroRNA-492 is processed
from the keratin 19 gene and up-regulated in metastatic
hepatoblastoma. Hepatology. 53:833–842. 2011.PubMed/NCBI
|
|
15
|
Hu H, Du L, Nagabayashi G, Seeger RC and
Gatti RA: ATM is down-regulated by N-Myc-regulated microRNA-421.
Proc Natl Acad Sci USA. 107:1506–1511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Otsuka M, Zheng M, Hayashi M, Lee JD,
Yoshino O, Lin S and Han J: Impaired microRNA processing causes
corpus luteum insufficiency and infertility in mice. J Clin Invest.
118:1944–1954. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaksman O, Stavnes HT, Kærn J, Trope CG,
Davidson B and Reich R: miRNA profiling along tumor progression in
ovarian carcinoma. J Cell Mol Med. 15:1593–602. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laios A, O’Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D’Arcy T,
McGuinness E, Sheils O, Sheppard B and O’Leary J: Potential role of
miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer.
7:352008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D,
Cross CL, Bostick-Bruton F and Reed E: Association between the
level of ERCC-1 expression and the repair of cisplatin-induced DNA
damage in human ovarian cancer cells. Anticancer Res. 20:645–652.
2000.PubMed/NCBI
|
|
20
|
Teodoridis JM, Hall J, Marsh S, Kannall
HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G
and Brown R: CpG island methylation of DNA damage response genes in
advanced ovarian cancer. Cancer Res. 65:8961–8967. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsuoka S, Ballif BA, Smogorzewska A,
McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini
N, Lerenthal Y, Shiloh Y, Gygi SP and Elledge SJ: ATM and ATR
substrate analysis reveals extensive protein networks responsive to
DNA damage. Science. 316:1160–1166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thiagalingam S, Cheng KH, Lee HJ, Mineva
N, Thiagalingam A and Ponte JF: Histone deacetylases: unique
players in shaping the epigenetic histone code. Ann N Y Acad Sci.
983:84–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee H, Rezai-Zadeh N and Seto E: Negative
regulation of histone deacetylase 8 activity by cyclic
AMP-dependent protein kinase A. Mol Cell Biol. 24:765–773. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Simboeck E and Di Croce L: HDAC1, a novel
marker for benign teratomas. EMBO J. 29:3992–4007. 2010. View Article : Google Scholar
|
